Skip to content

Sustainability, competitiveness, strategic autonomy: a new European model for health

  • Rome
  • 11 November 2026

        Europe remains among the world’s leading pharmaceutical producers and exporters, and Italy is one of its main manufacturing hubs. However, the innovation base underlying this leadership is thinning out. Between 2010 and 2022, European pharmaceutical research and development spending grew by 4.4% per year, compared to 5.5% in the United States and 20.7% in China; over a decade, the share of clinical trials conducted within the European Economic Area dropped from 22% to 12%. The limitation lies neither in the quality of the science nor in manufacturing capacity, but rather in the difficulty of translating them into businesses and patient access: a single regulatory authority is matched by twenty-seven pricing and reimbursement systems; therefore, it takes 532 days on average between European authorization and the actual availability of a drug.

        This picture is compounded by the American Most Favored Nation (MFN) policy, which anchors the prices of the world’s premier market to those of a basket of developed countries, including Italy. The mechanism looks at prices actually paid, including confidential rebates that companies negotiate with national authorities. A discount granted in a European country thus risks lowering the price in the United States as well, where revenues are much higher, and it may become advantageous for a company to delay or forgo the launch of a new drug in Europe. Early data points in this direction: in the European countries included in the basket, launches dropped by 37.8% in the year following the introduction of the MFN, compared to 10.5% in the United States. While the causal link is not yet proven, this does call into question the expectation that innovation can reach everyone—one of the foundations of the European social compact. The response cannot come from a sum of national reactions: a common negotiating position is needed.

        In Italy, the core issue is planning. Public pharmaceutical spending is subject to legally mandated ceilings, and in 2025 direct purchases—drugs bought by public healthcare facilities, largely hospitals—exceeded the cap by approximately €4.7 billion. When this happens, the payback mechanism is triggered: companies are required to refund half of the overspending, while the other half is borne by the Regions. Since this now happens every year, a company cannot know in advance how much it will actually collect, making the Italian market less attractive. Budget policy is moving in two directions: raising the caps and reducing the share that each company must return in proportion to the investments made in Italy in production and research.

        More broadly, the ratio of healthcare spending to GDP, taken on its own, is an unreliable indicator: what matters is what that spending contains and how much of it constitutes investment. However, European statistical rules do not allow pharmaceutical spending to be accounted for as investment, not even for drugs that generate benefits over many years. The path forward therefore lies elsewhere, passing through four interventions. The first is to use data on treatment outcomes to redistribute resources among prevention, hospitals, and community care. The second is to overhaul the pharmaceutical formulary—the list of drugs reimbursed by the National Health Service—not only by adding new ones, but also by removing obsolete ones. The third is to negotiate prices based on outcomes achieved in patients. The fourth, for well-established drugs, is to genuinely apply multi-winner tenders, already provided for by law but rarely used, which guarantee multiple suppliers and greater competition. All of this presupposes a stronger coordination between the State and the Regions than currently exists.

        Furthermore, the way we determine the value of a drug needs to change. The price should reflect the benefits actually gained by patients, measured over time and not just at launch: many therapies cost today and pay off years later in avoided hospitalizations and years of active life. This does not mean paying more for everything presented as innovative: value must be proven.

        Two conditions remain weak. The first is data: the European Health Data Space offers a potential competitive advantage, but implementation timelines are long, and a restrictive interpretation of privacy rules is already blocking industrial research and development. The second is organization: in public hospitals, clinical research often relies on the goodwill of individuals, while the system continues to pay for services based on quantity rather than on patient health outcomes.

        Healthcare spending is an investment—in avoided disease costs, human capital, and economic activity—and it is a component of security, on par with energy and defense. It requires multi-year planning and measures adopted in concert rather than sequentially. The ingredients are there. Systematizing them swiftly is the condition for Europe to preserve and strengthen its role in the life sciences.